Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study

BACKGROUND: Patients with pancreatic ductal adenocarcinoma (PDAC) are increasingly receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline resectable and locally advanced disease. However, the specific role of additional adjuvant chemotherapy (AC) in these patients is u...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Ning, Wu, Wenchuan, Liu, Siyao, Xie, Yuqi, Yin, Hanlin, Chen, Qiangda, He, Taochen, Xu, Zhihang, Wang, Wenquan, Yu, Jun, Liu, Liang, Lou, Wenhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583928/
https://www.ncbi.nlm.nih.gov/pubmed/37418574
http://dx.doi.org/10.1097/JS9.0000000000000589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583928/
https://www.ncbi.nlm.nih.gov/pubmed/37418574
http://dx.doi.org/10.1097/JS9.0000000000000589

Ejemplares similares